Tri-Institutional Therapeutics Discovery Institute Has Selected Scilligence Informatics Platforms to Facilitate Drug Discovery R&D
Boston, October 1, 2014 – Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) announces today that it has selected Scilligence ELN, RegMol and Inventory for facilitating collaborations and centralized data management in drug discovery R&D. “We’re excited to bring these Scilligence tools onboard and know that their innovative systems will help us to quickly advance our research toward new therapeutics”, said Dr. Michael Foley, a celebrated industry veteran and Tri-I TDI’s Sanders Director.
About Tri-Institutional Therapeutics Discovery Institute
The Tri-Institutional Therapeutics Discovery Institute is a unique partnership among three world-renowned scientific and medical institutions: Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College. The Institute works to more effectively develop therapeutics that arise from discoveries made in basic science labs. With a focus on early-stage drug discovery, the Institute provides expertise in medicinal chemistry and compound screening, and conducts “proof of concept” studies needed to demonstrate that drug candidates can successfully alter the course of a disease.
The Institute also works to provide high-quality opportunities for training students and post-doctoral fellows, to deepen faculty involvement in drug discovery, and to support translational research by leveraging the expertise of all three academic institutions and industry partners.
An independent non-profit corporation with its own Board of Directors and Scientific Advisory Board, the Institute will facilitate more efficient sharing of core facilities among the three partner institutions and will form industry partnerships with pharmaceutical and biotech companies to further advance drug research. It will seek to create intellectual property that can be further developed by an open field of industry collaborators.
About Scilligence Corporation
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.